BioAxone Therapeutic has reported that the FDA has granted orphan-drug status to its drug candidate Cethrin, which is currently in a Phase I/IIa clinical trial for patients with acute thoracic and cervical spinal cord injuries.

There is currently no effective treatment for acute spinal cord injury, a condition that can lead to complete and permanent loss of sensory and motor functions and require life-long specialized care for the vast majority of patients. Spinal cord injury has a dramatic impact on the quality of life of patients and those who care for them. In vitro as well as in vivo studies have demonstrated the neuro-protective and neuro-regenerative properties of Cethrin, underscoring the potential benefits of this treatment for patients with acute spinal cord injury.